Skip to main content
. 2021 Sep 26;16(5):687–695. doi: 10.1007/s11523-021-00839-w

Fig. 2.

Fig. 2.

Adverse events possibly causally related to treatment and occurring in ≥ 10% of patients in either treatment arm in the FLAURA trial (n = 279 and 277 receiving osimertinib and comparator EGFR-TKIs) [10]. AEs adverse events, ALT alanine aminotransferase, AST aspartate aminotransferase, EGFR-TKIs epidermal growth factor receptor tyrosine kinase inhibitors, ϴ zero incidence of grade ≥ 3 AEs